Gene · 1806
Papers4,420
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
921 to 940 of 4,420
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer. | Asian Pac J Cancer Prev | 2022 | 35345374 | PubTator, text mining | PubMed |
| Pharmacogenomic landscape of Indian population using whole genomes. | Clin Transl Sci | 2022 | 35338580 | PubTator, text mining | PubMed |
| Tumor-associated macrophages related signature in glioma. | Aging (Albany NY) | 2022 | 35332109 | PubTator, text mining | PubMed |
| Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care. | Cancers (Basel) | 2022 | 35326699 | PubTator, text mining | PubMed |
| MicroRNA as a Potential Therapeutic Molecule in Cancer. | Cells | 2022 | 35326459 | PubTator, text mining | PubMed |
| Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping. | Oncologist | 2022 | 35325223 | PubTator, text mining | PubMed |
| In Reply. | Oncologist | 2022 | 35325206 | PubTator, text mining | PubMed |
| Consensus on potential biomarkers developed for use in clinical tests for schizophrenia. | Gen Psychiatr | 2022 | 35309241 | PubTator, text mining | PubMed |
| A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing. | Br J Cancer | 2022 | 35306539 | PubTator, text mining | PubMed |
| Modern developments in germline pharmacogenomics for oncology prescribing. | CA Cancer J Clin | 2022 | 35302652 | PubTator, text mining | PubMed |
| Pediatric sleep outcomes after endoscopy-directed simultaneous lingual tonsillectomy and epiglottopexy. | J Otolaryngol Head Neck Surg | 2022 | 35287751 | PubTator, text mining | PubMed |
| [Profound survival benefit with concurrent chemotherapy: insights from a Chinese phase III trial in older patients with esophageal cancer]. | Strahlenther Onkol | 2022 | 35286400 | PubTator, text mining | PubMed |
| SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation. | Trials | 2022 | 35279214 | PubTator, text mining | PubMed |
| Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. | Cancers (Basel) | 2022 | 35267558 | PubTator, text mining | PubMed |
| Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted. | Cancers (Basel) | 2022 | 35267440 | PubTator, text mining | PubMed |
| Optimizing the prescription doses and tolerability of systemic therapy in head and neck cancer patients. | Curr Opin Oncol | 2022 | 35266908 | PubTator, text mining | PubMed |
| Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial. | Front Oncol | 2022 | 35251955 | PubTator, text mining | PubMed |
| Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020. | Cancer Manag Res | 2022 | 35250310 | PubTator, text mining | PubMed |
| The role of endogenous versus exogenous sources in the exposome of putative genotoxins and consequences for risk assessment. | Arch Toxicol | 2022 | 35249149 | PubTator, text mining | PubMed |
| Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing. | Sci Adv | 2022 | 35245110 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1806/papers?page=47